Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Lupin receives US FDA tentative approval for raltegravir tablets, USP: Our Bureau, Mumbai Friday, November 8, 2024, 17:45 Hrs [IST] Global pharma major Lupin Limited (Lupin) annou ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and may be eligible to receive a 180 ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

whilst “American” Merck (now Merck & Co. in the US or Merck Sharp & Dohme (MSD) elsewhere) was compulsorily split off from its Germany parent company (Merck KGaA) at the same time. Bayer also ...